Only 13 spots left

~13 spots leftby Dec 2026

DARZALEX FASPRO® for Peripheral Neuropathy
(Dara-MGUS Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byKimberley Doucette, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Georgetown University

Must not be taking: Anti-CD-38 therapies

Disqualifiers: Multiple myeloma, Diabetes, COPD, others

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial is testing an injectable medication called DARZALEX FASPRO® in patients with MGUS who have nerve damage. The goal is to see if this treatment can improve their nerve-related symptoms. The medication works by helping the immune system target abnormal cells and improving absorption of the drug.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are taking medications for conditions like diabetes, vitamin deficiencies, or chronic alcohol consumption, you may be excluded from the trial.

Research Team

Kimberley Doucette, MD

Principal Investigator

Georgetown University

Eligibility Criteria

Adults with MGUS-related peripheral neuropathy, who have certain levels of nerve damage and disability, can join. They must have good bone marrow and liver function, use effective birth control, and not be pregnant or breastfeeding. People with prior daratumumab exposure, HIV, hepatitis B/C, other cancers like multiple myeloma or serious medical conditions that could risk safety are excluded.

Inclusion Criteria

I have chronic demyelinating neuropathy and MGUS with an IgM peak.

I have trouble with coordination or my pain level is above moderate.

My bone marrow and liver are working well.

See 8 more

Exclusion Criteria

My lung function is less than half of what is expected for someone my age and size.

I have a condition like diabetes or vitamin deficiency that might be causing my nerve pain.

I have a serious heart condition.

See 10 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Treatment

Participants receive DARZALEX FASPRO® once a week for two months, followed by every other week from months 3 to month 6

6 months

Weekly visits for 2 months, then bi-weekly visits for 4 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

Regular assessments at 3, 6, 9, and 12 months

Treatment Details

Interventions

Daratumumab (Monoclonal Antibodies)

Trial OverviewThe trial tests DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for improving nerve damage in MGUS patients. Participants will undergo initial testing to assess their condition before receiving the medication weekly for two months then every other week until month six.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Daratumumab and hyaluronidase-fihjExperimental Treatment1 Intervention